ImmunoGuide® Enzyme immunoassay (ELISA) for the determination of free Aflibercept in serum and plasma samples. For research use only, not for use in diagnostic procedures.<br><br>
The drug Aflibercept (trade names Eylea®, Zaltrap®) is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of human IgG1. Aflibercept has broad affinity for all ligands that bind to these receptors, including isoforms of VEGF-A, VEGF-B, and placental growth factors. Aflibercept demonstrated anti-tumor effects and antiangiogenic activity as a single agent and enhanced activity in combination with chemotherapy.<br><br>
Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Aflibercept in order to potentially avoid some side effects with a reliable method might be beneficial.
- Assay Description:
- 60 min. incubation (RT) + 30 min. (RT) + 15 min. (RT) = 1 hour, 45 min. total incubation time
- Catalog number:
- TM09028
- configuration:
- 96 Determinations, 12x8 removable strips
- controls:
- None provided
- design:
- Sandwich enzyme immunoassay (ELISA) technique
- FDA Status:
- For research use only, not for use in diagnostic procedures
- MSDS:
- Available upon request
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Other names:
- Eylea®, Zaltrap®
- Protocol:
- Sample types:
- Serum and plasma
- Sample volume:
- 10 µL
- standards:
- 5 standards, ready to use
- Standard range:
- 0 / 6 - 200 ng/mL
- storage:
- 2 - 8 °C
- sensitivity:
- 5 ng/mL
- Species:
- Human
- Additional info:
